Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma.

ABSTRACT: Hepatocellular carcinoma (HCC) is the third most frequent source of deaths associated with cancer after lung cancer in the world despite recent innovative treatment techniques. Liver transplantation, hepatic resection, and percutaneous ablation techniques hold great promise as potentially curative treatments for patients at early stages. Nevertheless, most of the patients are not suitable for these curative treatments due to their advanced disease stages at the time of diagnosis. Food and Drug Administration (FDA) approved tyrosine kinase inhibitor, sorafenib is a standard therapy for advanced-stage HCC patients which extends overall survival for several months. However, its therapeutic efficacy is restricted by adverse events and drug resistance which limits the number of patients benefit

SUBMITTER: Eresen A 

PROVIDER: S-EPMC8743717 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature